A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Myelofibrosis
Interventions
DRUG

BMS-986158

Specified dose on specified days

DRUG

Ruxolitinib

Specified dose on specified days

DRUG

Fedratinib

Specified dose on specified days

Trial Locations (53)

1088

Local Institution - 0075, Budapest

2148

Local Institution - 0036, Blacktown

2500

Local Institution - 0032, Wollongong

3002

Local Institution - 0007, East Melbourne

3084

Local Institution - 0006, Heidelberg

4032

Local Institution - 0074, Debrecen

4400

Local Institution - 0072, Nyíregyháza

6005

Local Institution - 0015, West Perth

6009

Local Institution - 0041, Nedlands

6725

Local Institution - 0073, Szeged

12462

Local Institution - 0061, Chaïdári

13273

Local Institution - 0008, Marseille

13620

Local Institution - 0049, Seongnam

15224

Local Institution - 0042, Pittsburgh

23538

Local Institution - 0050, Lübeck

25123

Local Institution - 0002, Brescia

27514

Local Institution - 0076, Chapel Hill

28034

Local Institution - 0054, Madrid

28041

Local Institution - 0026, Madrid

29200

Local Institution - 0030, Brest

32746

Local Institution - 0090, Lake Mary

37007

Local Institution - 0021, Salamanca

37134

Local Institution - 0012, Verona

39008

Local Institution - 0029, Santander

40138

Local Institution - 0003, Bologna

45122

Local Institution - 0039, Essen

46026

Local Institution - 0094, Valencia

48109

Local Institution - 0033, Ann Arbor

50134

Local Institution - 0001, Florence

70112

Local Institution - 0043, New Orleans

75010

Local Institution - 0011, Paris

85435

Local Institution - 0068, Erding

92663

Local Institution - 0069, Newport Beach

94800

Local Institution - 0010, Villejuif

400015

Local Institution - 0051, Cluj-Napoca

4910021

Local Institution - 0018, Petah Tikva

5262100

Local Institution - 0017, Ramat Gan

6423906

Local Institution - 0019, Tel Aviv

8410101

Local Institution - 0086, Beersheba

9112001

Local Institution - 0016, Jerusalem

01655

Local Institution - 0038, Worcester

07601

Local Institution - 0045, Hackensack

06202

Local Institution - 0027, Nice

09116

Local Institution - 0040, Chemnitz

06120

Local Institution - 0035, Halle

570 10

Local Institution - 0047, Thessaloniki

76-200

Local Institution - 0077, Słupsk

80-952

Local Institution - 0062, Gdansk

022328

Local Institution - 0052, Bucuresti

050098

Local Institution - 0083, Bucharest

05505

Local Institution - 0048, Seoul

06591

Local Institution - 0053, Seoul

08916

Local Institution - 0020, Badalona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04817007 - A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | Biotech Hunter | Biotech Hunter